Advertisement
Skip to Content

CytoSorbents Corp CTSO Stock Quote

| Rating as of

NASDAQ: CTSO

Last close prices updated as of Feb 01, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 2.86
  • Sector Healthcare
  • Industry Medical Devices
  • Investment Style Small Blend
  • Day Range 2.76  –  3.10
  • Year Range 1.03  –  4.15
  • Market Cap 132.2162 Mil
  • Volume / Avg 198,275.0 /  203,581.3
  • Price / Sales 3.96
  • Price / Book 3.19
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis CTSO

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CTSO

Company Profile CTSO

Business Description

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.

Contact
7 Deer Park Drive, Suite K
Monmouth Junction, NJ, 08852
Industry Medical Devices
Employees 221

FAQs for CytoSorbents Corp Stock

No. CTSO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CTSO’s market cap is 132.22 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CTSO’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CTSO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CTSO’s historical performance against its industry peers and the overall market.